Preoperative systemic chemotherapy does not benefit for appendiceal pseudomyxoma peritonei
Peritoneal Surface Malignancy
Retrospective cohort study
Hyperthermic Intraperitoneal Chemotherapy
Appendix
03 medical and health sciences
Percutaneous Coronary Intervention
0302 clinical medicine
Pathological
Ovarian cancer
Management of Peritoneal Carcinomatosis from Digestive Tract
Health Sciences
Humans
Chemotherapy
Cytoreductive surgery
Pseudomyxoma peritonei
Perioperative
Internal medicine
Biology
Peritoneal Neoplasms
Retrospective Studies
Cancer
Intraperitoneal Chemotherapy
Gastroenterology
Paleontology
Hyperthermia, Induced
Cytoreduction Surgical Procedures
Diagnosis and Management of Appendicitis
Pseudomyxoma Peritonei
Combined Modality Therapy
3. Good health
Survival Rate
Hyperthermic intraperitoneal chemotherapy
Myocardial infarction
Appendiceal Neoplasms
Genomic Studies and Treatment of Ovarian Carcinoma
Reproductive Medicine
Emergency Medicine
Medicine
Conventional PCI
Surgery
DOI:
10.1111/ans.18041
Publication Date:
2022-09-22T16:20:50Z
AUTHORS (8)
ABSTRACT
AbstractBackgroundPseudomyxoma peritonei (PMP) is a clinically malignant tumour syndrome mainly derived from mucin‐producing appendiceal tumours. This study aimed to explore the effect of preoperative systemic chemotherapy (PSC) before cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) on the safety and postoperative survival in patients with appendiceal PMP.MethodsWe performed a retrospective analysis including consecutive patients with PMP undergoing primary surgery between January, 2008 and December, 2019 in Aerospace Center Hospital. The clinical data and postoperative survival were compared between PSC group and non‐PSC group.ResultsSeven hundred and fifty patients were included in the study. Significant differences were found between PSC group and non‐PSC group on clinicopathological data and perioperative outcomes and the independent risk factor of serious complications was blood loss >1000 mL (P = 0.026). Shorter median overall survival (OS) was found (42 months, 95% CI 31.9–52.1) in PSC group than that (67 months 95% CI 44.5–89.5) in non‐PSC group. In the stratified study with PCI < 20, CC 0/1 and low‐grade pathological subtype, the OS from non‐PSC group was significantly better than that in PSC group (log rank P‐values are <0.001, 0.006 and <0.001, respectively). Multivariate survival analysis showed that CC 0/1, HIPEC, PCI < 20 and low‐grade pathological subtype were the independent prognostic factors for better OS.ConclusionsPSC does not increase the risk of major perioperative complications in patients with appendiceal PMP, but it also does not bring postoperative survival benefits to patients either.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (20)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....